RE:RE:Today I must be the only one working? : ). Just got off work & haven't gotten to all of the posts, but a quick review of the data looks very reassuring. Firstly, all data after 90 days is not very meaningful to me. There are just too many pending patients to make any valid conclusions. The most meaningful data to focus on is the 90 day CR & the potential CR in "optimized" patients. Unfortunately, a further distinction wasn't made in the degree of optimization (partial vs full optimization).
Sorry if I'm recapitulating here, but a 60% CR in evaluable patients at 90 days, which is currently a "minimum" CR rate at this data juncture, is a very good sign. At the initial 90 day assessment (post primary treatment), there were 4 of 23 (17.4%) that were assessed as PRs & 3 of 23 (13%) that are still pending. The difference in the reported CR (52%) & the CR in "evaluable patients" (60%) indicates that 2 of the 4 PRs became CR after further PR analysis (possibly > 2 of 4 as the other two are still awaiting PR clarification). Assuming all 3 pending patients are CR & including 2 of 4 PRs converting to CR, that would currently give us a 74% CR (17 of 23). If all 4 PRs are found to be CR, we would reach 19 of 23 CRs, or an 82.6% CR rate as reported.
This data is very promising & met my more measured/less emotional expectations. The thoughtless selling today has provided another great buying opportunity. GLTAL!